Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

Monopar Therapeutics (MNPR) will present two abstracts on its investigational Wilson disease therapy ALXN1840 at AASLD’s Liver Meeting, November 5–9, 2026.

Rhea-AI Summary

Monopar Therapeutics (MNPR) will present two abstracts on its investigational Wilson disease therapy ALXN1840 at AASLD’s Liver Meeting, November 5–9, 2026.

Frederick K. Askari will present Phase 3 FoCus baseline findings on liver, neurologic and psychiatric disease burden on November 8, with a companion e-poster available online. Aftab Ala will present a poster on molybdenum balance in patients treated with ALXN1840 on November 5. The meeting takes place in Denver. Presentation materials will be available on Monopar’s investor website after each presentation.

Key Terms

phase 3, wilson disease, hepatic, treatment-naïve

4 terms

phase 3 medical

"baseline Wilson disease characteristics from the Phase 3 FoCus trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

wilson disease medical

"the Company’s investigational therapy for Wilson disease"

A genetic disorder that prevents the body from removing excess copper, causing copper to build up mainly in the liver and brain and leading to liver disease, movement problems, and cognitive or psychiatric symptoms. Investors pay attention because tests, drugs, gene therapies or diagnostic tools for this condition can drive regulatory approvals, clinical trial risk, and niche market opportunities; think of it as a small but high-need market where a successful treatment can meaningfully change company value.

hepatic medical

"characterizing hepatic, neurologic, and psychiatric disease burden"

Pertaining to the liver; 'hepatic' describes anything involving the liver’s structure or function, such as blood flow, metabolism, or disease. Investors care because liver effects are a common reason drugs are halted, reworked, or carry extra regulatory scrutiny and costs—think of the liver as the body’s filter or engine: problems there can change a product’s safety profile, timelines, and commercial value.

treatment-naïve medical

"in both treatment-naïve and treatment-experienced patients"

Patients described as treatment-naïve have not previously received the therapy being studied or other prior treatments for the same condition, so their bodies are ‘untouched’ by those drugs. For investors, this matters because results in a treatment-naïve group show how a therapy performs without prior drug effects, influence trial design and regulatory labeling, and help estimate the size and profile of the initial market—like testing a new seed in a garden that has never been treated before.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company’s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting^® 2026, taking place Nov. 5–9, 2026, at the Colorado Convention Center in Denver, Colorado.

As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-naïve and treatment-experienced patients. These findings will also be available as a companion e-poster via the AASLD website.

Additionally, Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., will present a poster on molybdenum balance in patients treated with ALXN1840.

Presentation Details

Oral Presentation

Title: Residual Hepatic, Neurologic, and Psychiatric Disease Burden in Treatment-Experienced Patients with Wilson Disease: Baseline Findings from the FoCus Phase 3 Trial
Presenter: Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program, University of Michigan Health System
Session: Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries
Publication Number: 0198
Date and Time: Sunday, Nov. 8, 2026, 12:15 p.m. to 12:30 p.m. MT

Companion E-Poster

Availability: An e-poster of the oral presentation will be available via the AASLD website. 

Poster Presentation

Title: Neutral Molybdenum Balance and Lack of Molybdenum Toxicity in Subjects Treated with Tiomolibdate Choline Supports Safety Profile of TMC
Presenter: Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Consultant Hepatologist, Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London
Session: Poster Session I: Metabolic and Genetic Disease
Publication Number: 1420
Date and Time: Thursday, Nov. 5, 2026, 12:00 p.m. to 1:00 p.m. MT

The abstracts are available on the AASLD conference website. Presentation materials will be made available in the Investors section of Monopar’s website at www.monopartx.com following each presentation.

About Wilson Disease

Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. Caused by mutations in the ATP7B gene, the disease impairs the body’s ability to excrete copper, resulting in toxic copper accumulation in the liver, brain, and other organs and potentially fatal outcomes if untreated.

About ALXN1840

ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage candidate ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to, uncertainties related to the regulatory and approval process for ALXN1840, and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com

Follow Monopar on social media for updates:
X: @MonoparTx | LinkedIn: Monopar Therapeutics